Form 4: Vir Biotechnology Director Janet Napolitano Reports RSU and Option Acquisitions, Alongside Planned Stock Sale

Vir Biotechnology, Inc. Director Janet Napolitano reported the acquisition of 8,000 restricted stock units and 16,000 stock options, alongside the sale of 3,200 common shares under a pre-arranged trading plan.

Summary

• Janet Napolitano, a Director of Vir Biotechnology, Inc. (VIR), reported transactions involving the company's securities.
• On May 30, 2025, Ms. Napolitano acquired 8,000 restricted stock units (RSUs) at a price of $0, which will vest in full on May 30, 2026, as part of the Issuer's Equity Incentive Plan.
• Also on May 30, 2025, she acquired 16,000 stock options with an exercise price of $4.94, which will vest and become exercisable in full on May 30, 2026, and expire on May 29, 2035.
• On June 2, 2025, Ms. Napolitano sold 3,200 shares of common stock at a weighted average price of $5.0465 per share, with prices ranging from $4.845 to $5.15.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2024.
• Following these transactions, Ms. Napolitano beneficially owns 16,416 shares of common stock and 16,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs and options by a director is generally positive as it aligns interests, while the sale of shares under a 10b5-1 plan is a routine event and not inherently negative, though some might view any insider selling with caution.

Positives

• Acquisition of 8,000 restricted stock units (RSUs) at $0, aligning director's interests with shareholders.
• Grant of 16,000 stock options with an exercise price of $4.94, providing future upside potential.

Negatives

• Sale of 3,200 common shares by a director, which could be perceived negatively by some investors, although it was conducted under a pre-arranged 10b5-1 plan.

Risks

• The sale of shares by an insider, even under a 10b5-1 plan, could be misinterpreted by the market as a lack of confidence, potentially impacting stock price.
• Future stock price volatility could affect the value of the remaining shares and the exercisability of the stock options.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider transactions.

Industry Context

This Form 4 filing details routine insider equity transactions for a director at a biotechnology company. Such transactions are common in the industry as part of executive compensation and personal financial management, often executed under pre-arranged trading plans (10b5-1) to avoid accusations of trading on material non-public information. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This document reports standard insider transactions (RSU grants, option grants, and stock sales under a 10b5-1 plan) which are common compensation and liquidity mechanisms across publicly traded companies, including those in the biotechnology sector. There are no specific company or project results to compare against global benchmarks or specific comparable companies within this filing.

Related Party Transactions

• Acquisition of 8,000 restricted stock units from the Issuer as part of the Equity Incentive Plan.
• Grant of 16,000 stock options from the Issuer.
• Sale of 3,200 common shares to the market, executed by a director of the Issuer.

Stakeholder Impact

• **Shareholders**: The acquisition of RSUs and options by a director can be seen as a positive signal of alignment with shareholder interests. The sale of shares, while under a 10b5-1 plan, represents a reduction in the director's direct common stock holdings.
• **Employees**: No direct impact mentioned, but the equity incentive plan is a general benefit for eligible employees and directors.

Next Steps

• The 8,000 restricted stock units are scheduled to vest in full on May 30, 2026.
• The 16,000 stock options are scheduled to vest and become exercisable in full on May 30, 2026.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

Keywords

Vir Biotechnology, VIR, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, RSU, Stock Options, 10b5-1 Plan, Director Transactions, Janet Napolitano, Equity Incentive Plan, Biotechnology Stock